Design,synthesis,and biological evaluation of novel FFA1 partial agonists bearing oxime ether scaffold

摘要

The free fatty acid receptor 1(FFA1)is a promising anti-diabetic target,and many FFA1 agonists including TAK-875 and AMG-837 are reached in clinical studies.However,the excessive lipophilicity of AMG-837(ClogP=6.81)might be a potential downside attributed to the clinical failure of AMG-837.In this study,we introduced the oxime ether moiety to replace the middle benzene of AMG-837 to reduce the lipophilicity.After comprehensive structure-activity relationship study,the optimal compound 7 was identified as a partial agonist with appropriate lipophilicity(EC_(50)=37.6 nM,Efficacy=71%,ClogP=4.73).Moreover,compound 7 exhibited significantly glucose-lowering effects in a dose-dependent manner,and the glucose-lowering effect was equivalent to that of TAK-875 at the dose of 20 mg/kg.In conclusion,this study provided a new series partial agonists bearing oxime ether scaffold,which is worthy for further exploration based on its excellent pharmacological activity and physicochemical property.